{"id":"liraglutid","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Nausea","drugRate":"2.9%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"1.7%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"1.4%","severity":"common","organSystem":""},{"effect":"Hypoglycemia (with sulfonylurea, glucose <54 mg/dL)","drugRate":"28.2%","severity":"common","organSystem":""},{"effect":"Erythema at injection site","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Pruritus at injection site","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Rash at injection site","drugRate":"2.5%","severity":"common","organSystem":""}],"contraindications":["Breastfeeding (mother)","C-cell hyperplasia of thyroid","Disorder of thyroid gland","Hypoglycemic disorder","Medullary thyroid carcinoma","Multiple endocrine neoplasia, type 2","Pancreatitis","Pregnancy, function"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Severe hypoglycemia (requiring assistance, with sulfonylurea)","drugRate":"0.7%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL4084119","moleculeType":"Protein","molecularWeight":"3751.26"},"aliases":["metformin"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Liraglutid","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:17:08.651890+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:17:28.251935+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:17:14.638599+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Liraglutid","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:17:14.954563+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucagon-like peptide 1 receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:17:16.088086+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4084119/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:17:15.756224+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"d2bfc30a-8392-4255-a4d8-fa0b8d1659b2","title":"LIRAGLUTIDE INJECTION, SOLUTION [ORBICULAR PHARMACEUTICAL TECHNOLOGIES PRIVATE LIMITED]"},"aiSummary":"Liraglutide, marketed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, is a GLP-1 receptor agonist primarily indicated for the treatment of type 2 diabetes mellitus. A key strength of Liraglutide is its well-established mechanism and market presence, with a key composition patent expiring in 2028. The primary risk is the potential increase in competition as the patent expiration approaches, which could impact market share and revenue.","ecosystem":[],"mechanism":{"target":"Glucagon-like peptide 1 receptor"},"_scrapedAt":"2026-03-28T06:12:03.376Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:17:28.252050+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Diabetes mellitus type 2","diseaseId":"diabetes-mellitus-type-2","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Weight loss","diseaseId":"weight-loss","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06439056","phase":"PHASE1","title":"Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D","status":"COMPLETED","sponsor":"Nanexa AB","startDate":"2024-05-27","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT03087032","phase":"PHASE4","title":"Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2019-01-10","conditions":"Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)","enrollment":164},{"nctId":"NCT02417103","phase":"PHASE3","title":"Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2011-12","conditions":"Obesity","enrollment":2},{"nctId":"NCT03449654","phase":"PHASE4","title":"Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2017-10-26","conditions":"Diabetes Mellitus, Type 2","enrollment":102},{"nctId":"NCT03961659","phase":"NA","title":"Effects of Liraglutid, Dapagliflozin and Acarbose on the Cognitive Function, Olfactory Function, and Odor-induced Brain Activation in Overweight/Obese T2DM Patients Controlled Inadequately With Metformin Monotherapy.","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2019-05","conditions":"Type 2 Diabetes Mellitus, Obesity, Cognitive Impairment","enrollment":87},{"nctId":"NCT01472640","phase":"NA","title":"The Effect of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With and Without Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Flyvbjerg, Allan, DMSc","startDate":"2011-11","conditions":"Hyperglycemia, Chronic Heart Failure","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL4084119"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":9,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Liraglutid","genericName":"Liraglutid","companyName":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","companyId":"the-affiliated-nanjing-drum-tower-hospital-of-nanjing-university-medical-school","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:17:28.252050+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}